All In Biotech

Drug Trial Radar · NCT06268769

Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs

Multicentre, Open-label, Randomised, Two-arm, Parallel-group, Superiority Trial to Assess Bioavailability and Practicability of Two Once-daily Tacrolimus Formulations, Envarsus® Compared With Advagraf™, Administered in Kidney Transplant Recipients

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 322 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

322

Actual

Start

Mar 9, 2024

Primary completion

Feb 4, 2026

Study completion Nov 2028

Sponsor

Lead sponsor
Edward GeisslerAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Chiesi Pharmaceuticals GmbH
First posted
Feb 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare the bioavailability and practicability of two different formulations of tacrolimus in kidney transplant recipients. The main objective is to demonstrate that Envarsus® (test drug) has superior (higher) oral bioavailability compared with Advagraf™ (comparator drug) at 12 weeks after kidney transplantation. The trial also aims to compare the practicability (handling) of the two drugs using a series of pharmacokinetic parameters and to explore the relationship between drug bioavailability and long-term clinical outcomes, with a special focus on dose-dependent adverse reactions, measured until 3 years post-transplantation. The trial incorporates a pharmacokinetic sub-study designed to profile the peak tacrolimus blood concentration up to 6 hours after drug intake on the day of the 12-week study visit.

Conditions

  • Immunosuppression

Interventions

  • Tacrolimus PillDrug

    Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.

  • Tacrolimus capsuleDrug

    Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-normalised blood trough level of tacrolimus (concentration/dose ratio)Time frame: 12 weeks after kidney transplantation

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • University Hospital Aachen, Department of General, Visceral and Transplant Surgery

    Aachen, Germany

  • Charité Universitätsmedizin, Department of Nephrology and Medical Intensive Care

    Berlin, Germany

  • Knappschaft Clinic, University Hospital Bochum, Department of Surgery

    Bochum, Germany

  • University Hospital Dresden, Division of Nephrology

    Dresden, Germany

  • University Medical Center Hamburg-Eppendorf, Internal Medicine III (Nephrology, Rheumatology, Endocrinology)

    Hamburg, Germany

  • Hannover Medical School, Department of General, Visceral and Transplant Surgery

    Hanover, Germany

  • University Hospital Jena, Internal Medicine III, Nephrology

    Jena, Germany

  • University Medical Center of the Johannes Gutenberg University Mainz, Medical Clinic I. (Nephrology)

    Mainz, Germany

  • University Hospital Mannheim, Medical Clinic V

    Mannheim, Germany

  • LMU University Hospital Munich, Department of General, Visceral and Transplant Surgery

    Munich, Germany

  • University Hospital Münster, Medical Clinic D

    Münster, Germany

  • University Hospital Regensburg, Department of Nephrology

    Regensburg, Germany

  • University Hospital Würzburg, Medical Clinic I, Department of Nephrology

    Würzburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.